Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Bone Marrow Transplant
; 12(3): 217-20, 1993 Sep.
Article
en En
| MEDLINE
| ID: mdl-8241979
ABSTRACT
One dose of pentostatin was added to a standard cyclophosphamide (CY) based transplant regimen in two patients in an attempt to decrease the rate of non-engraftment in haploidentical allogeneic BMT. Despite a normal cardiac history and evaluation prior to transplant, both patients suffered fatal cardiac toxicity within 48 h of receiving the chemotherapy. This phenomenon was further investigated in an animal model. Laboratory rats were treated with progressive doses of CY in a range that produces acute cardiac toxicity. Successive groups of rats were treated with either pentostatin or fludarabine and CY at 400 mg/kg. Neither pentostatin nor fludarabine alone produced early mortality. However, a marked increase in early mortality was noted in those animals treated with pentostatin and high-dose CY. The addition of fludarabine did not increase the early toxicity of CY. Autopsy revealed no gross or microscopic abnormalities in the animals. The implications of adding agents that interfere with adenosine metabolism to CY based transplant regimens is discussed.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Choque Cardiogénico
/
Linfoma no Hodgkin
/
Pentostatina
/
Linfoma de Células B Grandes Difuso
/
Purgación de la Médula Ósea
/
Ciclofosfamida
Tipo de estudio:
Prognostic_studies
Límite:
Adult
/
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Año:
1993
Tipo del documento:
Article